In recent times, the market has seen an emergence of half-life drugs, which reduces the time of drugs to concentrate in the body. These drugs have an advantage of long-lasting action and reduced repeated intake of medicine. Therefore, an increase in the adoption rate of half-life therapies in hemophilia B treatment will drive the market growth.

PART 01: Executive summary

PART 02: Scope of the report

Market overview

Assumptions

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

Highlights

PART 05: Disease overview

PART 06: Pipeline analysis

PART 07: Market landscape

Market overview

Five forces analysis

PART 08: Market segmentation by disease type

Global hemophilia B drugs market

Global hemophilia B inhibitors market

PART 09: Market segmentation by type of therapy

Recombinant therapies

Plasma-derived therapies

PART 10: Market segmentation by type of disease

management

Prophylaxis

On-demand therapy

Inhibitor therapy

PART 11: Geographical segmentation

Factor IX drugs market in Americas

Factor IX drugs market in EMEA

Factor IX drugs market in APAC

PART 12: Market drivers

Shifting toward half-life drugs

Special designations promote novel launches

Growing pipeline with increased focus to meet unmet

demand

PART 13: Impact of drivers

PART 14: Market challenges

Emerging price war in the industry

Low penetration rate

Lack of complete remission

High entry barriers

PART 15: Impact of drivers and challenges

PART 16: Market trends

Increasing focus on gene therapy

Increase in investments in the production and

discovery

Strategic initiatives should lead to consolidation

PART 17: Vendor landscape

Competitive scenario

PART 18: Key vendor analysis

Biogen

CSL Behring

Novo Nordisk

Pfizer

Shire

PART 19: Appendix

List of abbreviations

PART 20: Explore Technavio